Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

Ian Creese; David R. Burt; Solomon H. Snyder

doi:10.1126/science.3854

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

Ian Creese, David R. Burt, Solomon H. Snyder

School of Medicine

Research output: Contribution to journal › Article › peer-review

1714 Scopus citations

Abstract

Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

Original language	English (US)
Pages (from-to)	481-483
Number of pages	3
Journal	Science
Volume	192
Issue number	4238
DOIs	https://doi.org/10.1126/science.3854
State	Published - Jan 1 1976

ASJC Scopus subject areas

General

Access to Document

10.1126/science.3854

Cite this

@article{84a56c4afd3f4a69b61271b25dfef18f,

title = "Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs",

abstract = "Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.",

author = "Ian Creese and Burt, {David R.} and Snyder, {Solomon H.}",

year = "1976",

month = jan,

day = "1",

doi = "10.1126/science.3854",

language = "English (US)",

volume = "192",

pages = "481--483",

journal = "Science",

issn = "0036-8075",

publisher = "American Association for the Advancement of Science",

number = "4238",

}

TY - JOUR

T1 - Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

AU - Creese, Ian

AU - Burt, David R.

AU - Snyder, Solomon H.

PY - 1976/1/1

Y1 - 1976/1/1

N2 - Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

AB - Tritiated haloperidol and tritiated dopamine label postsynaptic dopamine receptors in mammalian brain. Clinical potencies of butyrophenones, phenothiazines, and related drugs correlate closely with their ability to inhibit tritiated haloperidol binding. These binding methods provide a simple in vitro means for evaluating new drugs as potential antischizophrenic agents.

UR - http://www.scopus.com/inward/record.url?scp=0017255979&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0017255979&partnerID=8YFLogxK

U2 - 10.1126/science.3854

DO - 10.1126/science.3854

M3 - Article

C2 - 3854

AN - SCOPUS:0017255979

SN - 0036-8075

VL - 192

SP - 481

EP - 483

JO - Science

JF - Science

IS - 4238

ER -

Dopamine receptor binding predicts clinical and pharmacological potencies of antischizophrenic drugs

Abstract

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this